Non-Small Cell Lung Cancer
Conditions
Keywords
Lung Cancer
Brief summary
Researchers from Memorial Sloan-Kettering Cancer Center are conducting a research study on a Chinese herbal medicine known as Jin Fu Kang. We want to see if this can help patients with advanced lung cancer. Jin Fu Kang might reduce the growth of cancer or improve quality of life. You are eligible for this trial because your cancer has progressed after prior chemotherapy and your doctor has recommended further chemotherapy treatment. Lung cancer that has been confirmed and that has spread is called advanced cancer. There is no known permanent cure for advanced lung cancer, but chemotherapy may temporarily shrink the cancer and improve the quality of patients' lives.
Detailed description
Jin Fu Kang is a herbal medicine specially developed in China for the treatment of lung cancer. It is based on a traditional medicine that is widely used and appears to be safe. Although clinical trials in China suggest that Jin Fu Kang may be of benefit, it has never been researched in patients with lung cancer in the United States. As such, its risks and benefits are not fully understood. The scientific aims are to determine the toxicity of Jin Fu Kang/docetaxel combination treatment in patients with non-small cell lung cancer, to determine whether Jin Fu Kang alters the pharmacokinetics of docetaxel and to provide preliminary efficacy and survival data for Jin Fu Kang/docetaxel combination treatment in patients with non-small cell lung cancer.
Interventions
DRUGDocetaxel
DRUGJin Fu Kang
Sponsors
Memorial Sloan Kettering Cancer Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
-Patients must meet all of the following inclusion criteria: * Pathologic confirmation of stage III or IV NSCLC. * Docetaxel therapy for cancer is clinically indicated. * KPS\>=60% \*ANC\<1,000/mcl and Platelets\<100/mcl
Exclusion criteria
-Patients must meet none of the following
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the toxicity of Jin Fu Kang / docetaxel combination treatment in patients with previously treated non-small cell lung cancer. | — |
Secondary
| Measure | Time frame |
|---|---|
| To determine whether Jin Fu Kang alters the pharmacokinetics of docetaxel. | — |
| To provide preliminary efficacy and survival data for Jin Fu Kang / docetaxel combination treatment in patients with previously treated non-small cell lung cancer. | — |
Countries
United States
Outcome results
None listed